vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
36.66
+4.99 (15.77%)
May 14, 2026, 1:23 PM EDT - Market open
vTv Therapeutics Revenue
vTv Therapeutics had revenue of $36.84M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $36.84M, up 216,600.00% year-over-year.
Revenue (ttm)
$36.84M
Revenue Growth
+216,600.00%
P/S Ratio
12.32
Revenue / Employee
$1,416,885
Employees
26
Market Cap
454.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 1.02M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.02M | -1.99M | -49.61% |
| Dec 31, 2021 | 4.01M | -2.41M | -37.56% |
| Dec 31, 2020 | 6.41M | 3.65M | 132.05% |
| Dec 31, 2019 | 2.76M | -9.67M | -77.77% |
| Dec 31, 2018 | 12.43M | 12.14M | 4,172.85% |
| Dec 31, 2017 | 291.00K | -343.00K | -54.10% |
| Dec 31, 2016 | 634.00K | 115.00K | 22.16% |
| Dec 31, 2015 | 519.00K | -1.03M | -66.49% |
| Dec 31, 2014 | 1.55M | 573.00K | 58.71% |
| Dec 31, 2013 | 976.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 217.78M |
| Century Therapeutics | 109.16M |
| Enanta Pharmaceuticals | 69.21M |
| Invivyd | 53.43M |
| Verastem | 49.59M |
| C4 Therapeutics | 34.86M |
| X4 Pharmaceuticals | 9.01M |
VTVT News
- 21 hours ago - vTv Therapeutics reports Q1 EPS $1.65, consensus 21c - TheFly
- 21 hours ago - vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 days ago - vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - vTv Therapeutics to Participate in Upcoming May Investor Conferences - GlobeNewsWire
- 2 months ago - vTv Therapeutics to Participate in the 38th Annual ROTH Conference - GlobeNewsWire
- 2 months ago - vTv Therapeutics initiated with an Outperform at Evercore ISI - TheFly
- 2 months ago - vTv Therapeutics price target raised to $55 from $35 at Alliance Global - TheFly
- 2 months ago - vTv Therapeutics reports Q4 EPS (58c), consensus ($1.09) - TheFly